NCT03218501View on ClinicalTrials.gov

A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus

PHASE2CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

May 25, 2018

Study Completion Date

May 25, 2018

Conditions
Uremic Pruritus in Hemodialysis Patients
Interventions
DRUG

SK-1405 high dose

SK-1405 high dose is to be administered orally once daily for 2 weeks

DRUG

SK-1405 low dose

SK-1405 low dose is to be administered orally once daily for 2 weeks

DRUG

Placebo

Placebo is to be administered orally once daily for 2 weeks

Trial Locations (1)

Unknown

Investigational site (there may be other sites in this country), Tokyo

All Listed Sponsors
lead

Sanwa Kagaku Kenkyusho Co., Ltd.

INDUSTRY

NCT03218501 - A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus | Biotech Hunter | Biotech Hunter